Primary T lymphocytes as targets for gene therapy

Area of Science:

• Immunology
• Gene Therapy
• Cell Biology

Background:

• Peripheral blood T lymphocytes are a viable target for gene therapy due to ease of harvesting and expansion.
• Optimized gene transfer methods achieve high transduction efficiency (≥50%) in primary human lymphocytes using retroviral vectors.
• Various gene transfer techniques, including viral (adenoviral, AAV, lentiviral) and nonviral methods, are applicable to lymphocytes.

Purpose of the Study:

• To review the potential of T lymphocytes as targets for gene therapy.
• To highlight the successes and challenges of gene transfer into primary lymphocytes.
• To identify the limitations hindering clinical translation and suggest future research directions.

Main Methods:

• Review of existing literature on gene transfer into T lymphocytes.
• Analysis of transduction efficiencies using different vector systems (retroviral, adenoviral, AAV, lentiviral, nonviral).
• Evaluation of outcomes from in vitro studies and human clinical trials.

Main Results:

• High in vitro transduction efficiencies are achievable with optimized retroviral vectors.
• Clinical trials using retroviral vectors have been limited by low transgene expression levels.
• Immune responses against transgene products present a significant hurdle in clinical applications.

Conclusions:

• While T lymphocytes are amenable to gene transfer, clinical success is impeded by transgene expression and immunogenicity issues.
• Development of strategies to enhance transgene expression and mitigate immune responses is crucial for advancing T lymphocyte-based gene therapies.
• Further research is needed to overcome current limitations for effective clinical application.